Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 315824, 12 pages
http://dx.doi.org/10.1155/2014/315824
Research Article

Proteomic Analysis of Serum and Urine of HIV-Monoinfected and HIV/HCV-Coinfected Patients Undergoing Long Term Treatment with Nevirapine

1Research Institute for Health Sciences, Chiang Mai University, Chiang Mai 50200, Thailand
2Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
3Proteomics Research Laboratory, Genome Institute, National Center for Genetic Engineering and Biotechnology, Pathum Thani 12120, Thailand
4Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
5Institute of Molecular Biosciences, Mahidol University, Salaya Campus, 25/25 Phuttamonthol Sai 4, Nakorn Pathom 73170, Thailand

Received 3 September 2014; Revised 9 November 2014; Accepted 25 November 2014; Published 17 December 2014

Academic Editor: Robert Pichler

Copyright © 2014 Jeerang Wongtrakul et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. G. Deeks, S. R. Lewin, and D. V. Havlir, “The end of AIDS: HIV infection as a chronic disease,” The Lancet, vol. 382, no. 9903, pp. 1525–1533, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Andreoni, A. Giacometti, I. Maida, P. Meraviglia, D. Ripamonti, and L. Sarmati, “HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications,” European Review for Medical and Pharmacological Sciences, vol. 16, no. 11, pp. 1473–1483, 2012. View at Google Scholar · View at Scopus
  3. V. Soriano, E. Vispo, P. Labarga, J. Medrano, and P. Barreiro, “Viral hepatitis and HIV co-infection,” Antiviral Research, vol. 85, no. 1, pp. 303–315, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Sungkanuparph, A. Vibhagool, W. Manosuthi et al., “Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study,” Journal of the Medical Association of Thailand, vol. 87, no. 11, pp. 1349–1354, 2004. View at Google Scholar · View at Scopus
  5. C. S. Graham, L. R. Baden, E. Yu et al., “Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis,” Clinical Infectious Diseases, vol. 33, no. 4, pp. 562–569, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Soto, A. Sánchez-Quijano, L. Rodrigo et al., “Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis,” Journal of Hepatology, vol. 26, no. 1, pp. 1–5, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Martín-Carbonero, M. Núñez, J. González-Lahoz, and V. Soriano, “Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine,” HIV Clinical Trials, vol. 4, no. 2, pp. 115–120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Martínez, J. L. Blanco, J. A. Arnaiz et al., “Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy,” AIDS, vol. 15, no. 10, pp. 1261–1268, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. M. S. Sulkowski, D. L. Thomas, S. H. Mehta, R. E. Chaisson, and R. D. Moore, “Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections,” Hepatology, vol. 35, no. 1, pp. 182–189, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. J. A. Pineda and J. Macías, “Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy,” Journal of Antimicrobial Chemotherapy, vol. 55, no. 4, pp. 417–419, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. M. S. Sulkowski and Y. Benhamou, “Therapeutic issues in HIV/HCV-coinfected patients,” Journal of Viral Hepatitis, vol. 14, no. 6, pp. 371–386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Yunihastuti, R. A. Gani, L. A. Lesmana, H. Sundaru, and S. Djauzi, “Grade 3-4 liver enzyme elevation during HAART in HIV and hepatitis C co-infected adults.,” Acta medica Indonesiana, vol. 41, no. 3, pp. 130–135, 2009. View at Google Scholar · View at Scopus
  13. R. L. Murphy, “Defining the toxicity profile of nevirapine and other antiretroviral drugs,” Journal of Acquired Immune Deficiency Syndromes, vol. 34, supplement 1, pp. S15–S20, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Popovic, J. M. Shenton, J. Chen et al., “Nevirapine hypersensitivity,” Handbook of Experimental Pharmacology, no. 196, pp. 437–451, 2010. View at Publisher · View at Google Scholar
  15. A. Rivero, J. A. Mira, and J. A. Pineda, “Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 3, pp. 342–346, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. U. Spengler, M. Lichterfeld, and J. K. Rockstroh, “Antiretroviral drug toxicity—a challenge for the hepatologist?” Journal of Hepatology, vol. 36, no. 2, pp. 283–294, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Chen, B. M. Mannargudi, L. Xu, and J. Uetrecht, “Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash,” Chemical Research in Toxicology, vol. 21, no. 9, pp. 1862–1870, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. M. Sharma, Y. Li, M. Novalen, M. A. Hayes, and J. Uetrecht, “Bioactivation of nevirapine to a reactive quinone methide: implications for liver injury,” Chemical Research in Toxicology, vol. 25, no. 8, pp. 1708–1719, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Srivastava, L. Y. Lian, J. L. Maggs et al., “Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries,” Drug Metabolism and Disposition, vol. 38, no. 1, pp. 122–132, 2010. View at Publisher · View at Google Scholar
  20. AIDS Clinical Trials Group, Table for Grading Severity of Adult Adverse Experiences, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, Md, USA, 1992.
  21. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951. View at Google Scholar · View at Scopus
  22. N. Wikan, S. Khongwichit, W. Phuklia et al., “Comprehensive proteomic analysis of white blood cells from chikungunya fever patients of different severities,” Journal of Translational Medicine, vol. 12, no. 1, article 96, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Leecharoenkiat, T. Wannatung, P. Lithanatudom et al., “Increased oxidative metabolism is associated with erythroid precursor expansion in β0-thalassaemia/Hb E disease,” Blood Cells, Molecules, and Diseases, vol. 47, no. 3, pp. 143–157, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Ratanasopa, S. Chakane, M. Ilyas, C. Nantasenamat, and L. Bulow, “Trapping of human hemoglobin by haptoglobin: molecular mechanisms and clinical applications,” Antioxidants & Redox Signaling, vol. 18, no. 17, pp. 2364–2374, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Yamamoto, R. Nakao, T. Miyamura, H. Shimada, and E. Suematsu, “Significant decrease in the serum haptoglobin level after the antiretroviral therapy in patients infected with human immunodeficiency virus-1,” Journal of AIDS Research, vol. 5, pp. 71–75, 2003. View at Google Scholar
  26. F. Imbert-Bismut, V. Ratziu, L. Pieroni, F. Charlotte, Y. Benhamou, and T. Poynard, “Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study,” The Lancet, vol. 357, no. 9262, pp. 1069–1075, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Yang, K. D. Rudser, L. Higgins et al., “Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics,” Digestive Diseases and Sciences, vol. 56, no. 11, pp. 3305–3315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Bacq, Y. Schillio, J.-F. Brechot, A. de Muret, F. Dubois, and E.-H. Metman, “Decreased haptoglobin serum level in patients with chronic viral hepatitis C,” Gastroenterologie Clinique et Biologique, vol. 17, no. 5, pp. 364–369, 1993. View at Google Scholar · View at Scopus
  29. V. Papastergiou, E. Tsochatzis, and A. K. Burroughs, “Non-invasive assessment of liver fibrosis,” Annals of Gastroenterology, vol. 25, no. 3, pp. 218–231, 2012. View at Google Scholar · View at Scopus
  30. R. Williams, B. E. Speyer, and B. H. Billing, “Serum haptoglobin in liver disease,” Gut, vol. 2, pp. 297–303, 1961. View at Publisher · View at Google Scholar · View at Scopus